Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLT006
MIFTS: 45

Bilateral Breast Cancer

Categories: Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Bilateral Breast Cancer

About this section

MalaCards integrated aliases for Bilateral Breast Cancer:

Name: Bilateral Breast Cancer 12 55 15 72
Bilateral Breast Carcinoma 12 6

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:6741
NCIt 50 C8287
UMLS 72 C0281267
Sources

Summaries for Bilateral Breast Cancer

About this section
Disease Ontology : 12 A breast carcinoma that is characterized by an individual having breast cancer in both breasts, either simultaneously or at different times.

MalaCards based summary : Bilateral Breast Cancer, also known as bilateral breast carcinoma, is related to ataxia-telangiectasia and li-fraumeni syndrome. An important gene associated with Bilateral Breast Cancer is BRCA1 (BRCA1 DNA Repair Associated), and among its related pathways/superpathways are Gene Expression and Cell Cycle, Mitotic. The drugs Sargramostim and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and testes, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Bilateral Breast Cancer

About this section

Diseases related to Bilateral Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 225)
# Related Disease Score Top Affiliating Genes
1 ataxia-telangiectasia 30.3 CHEK2 BRCA1 ATM
2 li-fraumeni syndrome 30.0 CHEK2 BRCA2 BRCA1 ATM
3 comedo carcinoma 29.8 ESR1 ERBB2
4 lobular neoplasia 29.7 ESR1 ERBB2 BRCA1
5 papillary serous adenocarcinoma 29.7 PGR BRCA1
6 estrogen excess 29.4 PGR ESR1
7 gynecomastia 29.2 PGR ESR1
8 hereditary breast ovarian cancer syndrome 29.0 RAD51 CHEK2 BRCA2 BRCA1 ATM
9 in situ carcinoma 29.0 PGR ESR1 ERBB2 BRCA1
10 cervical adenocarcinoma 28.9 PGR ESR1 ERBB2
11 mammary paget's disease 28.7 PGR ESR1 ERBB2
12 tubular adenocarcinoma 28.7 PGR ESR1 ERBB2
13 breast fibroadenoma 28.7 PGR ESR1 ERBB2
14 endometrial adenocarcinoma 28.7 PGR ESR1 ERBB2
15 prostate cancer 28.5 ESR1 ERBB2 CHEK2 BRCA2 BRCA1
16 adenoid cystic carcinoma 28.3 PGR ERBB2 CHEK2 ATM
17 synchronous bilateral breast carcinoma 28.3 PGR ESR1 BRCA2 BRCA1 ATM
18 ductal carcinoma in situ 28.3 PGR ESR1 ERBB2 BRCA2 BRCA1
19 breast ductal carcinoma 28.2 PGR ESR1 ERBB2 BRCA1
20 breast disease 28.2 PGR ESR1 ERBB2 BRCA2 BRCA1
21 endometrial cancer 27.8 PGR ESR1 ERBB2 BRCA2 BRCA1
22 female breast cancer 27.7 PGR ESR1 ERBB2 BRCA2 BRCA1 ATM
23 ovarian cancer 27.0 PGR ESR1 ERBB2 CHEK2 BRCA2 BRCA1
24 breast cancer 26.9 RAD51 PGR FHIT ESR1 ERBB2 CHEK2
25 sporadic breast cancer 25.3 RAD51 PGR FHIT ESR1 ERBB2 CHEK2
26 hereditary site-specific ovarian cancer syndrome 10.6 BRCA2 BRCA1
27 breast-ovarian cancer, familial 1 10.5 BRCA2 BRCA1
28 pancreatic neuroendocrine tumor 10.5 BRCA2 ATM
29 peritoneum cancer 10.5 BRCA2 BRCA1
30 premature menopause 10.5 BRCA2 BRCA1
31 fallopian tube disease 10.5 BRCA2 BRCA1
32 fanconi anemia, complementation group u 10.4 RAD51 BRCA1
33 mutagen sensitivity 10.4 BRCA2 BRCA1
34 clivus chordoma 10.3 CHEK2 ATM
35 lynch syndrome i 10.3 BRCA2 BRCA1
36 fanconi anemia, complementation group d2 10.3 RAD51 BRCA2
37 breast giant fibroadenoma 10.3 ESR1 BRCA2
38 fanconi anemia, complementation group v 10.3 RAD51 BRCA1
39 uterine corpus serous adenocarcinoma 10.3 ERBB2 BRCA1
40 fanconi anemia, complementation group r 10.2 RAD51 BRCA1
41 fanconi anemia, complementation group q 10.2 RAD51 BRCA2 BRCA1
42 nijmegen breakage syndrome 10.1 CHEK2 BRCA1 ATM
43 fanconi anemia, complementation group t 10.1 RAD51 BRCA1
44 peutz-jeghers syndrome 10.1
45 li-fraumeni syndrome 2 10.1
46 t-cell prolymphocytic leukemia 10.1 CHEK2 ATM
47 congenital hypoplastic anemia 10.1 RAD51 BRCA2
48 infant gynecomastia 10.1
49 tuberculous salpingitis 10.0 ERBB2 BRCA2 BRCA1
50 fallopian tube adenocarcinoma 10.0 ERBB2 BRCA2 BRCA1

Graphical network of the top 20 diseases related to Bilateral Breast Cancer:



Diseases related to Bilateral Breast Cancer
Sources

Symptoms & Phenotypes for Bilateral Breast Cancer

About this section

GenomeRNAi Phenotypes related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10.58 ESR1
2 Decreased viability GR00221-A-2 10.58 CHEK2 ESR1 BRCA1
3 Decreased viability GR00221-A-3 10.58 ATM CHEK2 ERBB2 BRCA1
4 Decreased viability GR00221-A-4 10.58 ATM CHEK2 ERBB2 ESR1
5 Decreased viability GR00301-A 10.58 BRCA1
6 Decreased viability GR00342-S-2 10.58 CHEK2
7 Decreased viability GR00402-S-2 10.58 ATM CHEK2 ERBB2 ESR1 BRCA1
8 Decreased homologous recombination repair frequency GR00151-A-1 10.28 BRCA1 RAD51
9 Decreased homologous recombination repair frequency GR00151-A-2 10.28 BRCA1 RAD51
10 Decreased homologous recombination repair frequency GR00236-A-3 10.28 BRCA1 BRCA2 RAD51
11 Decreased viability in esophageal squamous lineage GR00235-A 9.87 BRCA1 BRCA2 CHEK2 ERBB2 ESR1 PGR
12 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.55 ATM BRCA1 BRCA2 CHEK2 RAD51
13 Decreased viability after ionizing radiation GR00232-A-2 9.54 ATM BRCA1 BRCA2
14 Decreased viability with cisplatin GR00101-A-4 9.43 BRCA1 BRCA2 RAD51
15 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.28 ATM BRCA1 BRCA2 CHEK2
16 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.28 ATM BRCA1 BRCA2 CHEK2 RAD51
17 Synthetic lethal with cisplatin GR00101-A-1 9.13 BRCA1 BRCA2 RAD51

MGI Mouse Phenotypes related to Bilateral Breast Cancer:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.11 ATM BRCA1 BRCA2 CHEK2 ERBB2 ESR1
2 embryo MP:0005380 10.02 ATM BRCA1 BRCA2 ERBB2 ESR1 PGR
3 homeostasis/metabolism MP:0005376 10.01 ATM BRCA1 BRCA2 CHEK2 ERBB2 ESR1
4 endocrine/exocrine gland MP:0005379 10 ATM BRCA1 BRCA2 CHEK2 ERBB2 ESR1
5 hematopoietic system MP:0005397 9.98 ATM BRCA1 BRCA2 CHEK2 ESR1 FHIT
6 immune system MP:0005387 9.91 ATM BRCA1 BRCA2 CHEK2 ESR1 FHIT
7 digestive/alimentary MP:0005381 9.89 BRCA1 BRCA2 ERBB2 ESR1 FHIT
8 integument MP:0010771 9.87 ATM BRCA1 BRCA2 ERBB2 ESR1 FHIT
9 mortality/aging MP:0010768 9.81 ATM BRCA1 BRCA2 CHEK2 ERBB2 ESR1
10 limbs/digits/tail MP:0005371 9.65 BRCA1 BRCA2 ERBB2 ESR1 PGR
11 neoplasm MP:0002006 9.56 ATM BRCA1 BRCA2 CHEK2 ERBB2 ESR1
12 reproductive system MP:0005389 9.1 ATM BRCA1 BRCA2 ERBB2 ESR1 PGR
Sources

Drugs & Therapeutics for Bilateral Breast Cancer

About this section

Drugs for Bilateral Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 40)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
2
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
3
leucovorin Approved Phase 2 58-05-9 143 6006
4
Sulindac Approved, Investigational Phase 2 38194-50-2 5352 1548887
5
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
6
Emodepside Investigational, Vet_approved Phase 2 155030-63-0
7 Alkylating Agents Phase 2
8 Micronutrients Phase 2
9 Trace Elements Phase 2
10 Vaccines Phase 2
11 Immunologic Factors Phase 2
12 Vitamins Phase 2
13 Vitamin B Complex Phase 2
14 Vitamin B9 Phase 2
15 Hematinics Phase 2
16 Immunosuppressive Agents Phase 2
17 Folate Phase 2
18 Nutrients Phase 2
19 Antineoplastic Agents, Alkylating Phase 2
20 Tubulin Modulators Phase 2
21 Epothilone B Phase 2
22 Epothilones Phase 2
23 Antimitotic Agents Phase 2
24 Estrogens Phase 2
25 Hormones Phase 2
26 Hormone Antagonists Phase 2
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
28 Antirheumatic Agents Phase 2
29 Analgesics Phase 2
30 Cyclooxygenase Inhibitors Phase 2
31 Anti-Inflammatory Agents, Non-Steroidal Phase 2
32 Steroid Synthesis Inhibitors Phase 2
33 Peripheral Nervous System Agents Phase 2
34 Analgesics, Non-Narcotic Phase 2
35 Anti-Inflammatory Agents Phase 2
36 Estrogen Receptor Antagonists Phase 2
37 Estrogen Antagonists Phase 2
38 Aromatase Inhibitors Phase 2
39
Progesterone Approved, Vet_approved Phase 1 57-83-0 5994
40 Progestins Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer Recruiting NCT03012100 Phase 2 Cyclophosphamide
2 A Phase II Randomized Study of Ixabepilone vs. Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2/Neu-Negative Breast Cancer Active, not recruiting NCT00877500 Phase 2 Ixabepilone
3 NSAID Effects on Clinical and Imaging Breast Biomarkers Active, not recruiting NCT01761877 Phase 2 Sulindac
4 A Phase 1b Study of M6620 in Combination With Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer Not yet recruiting NCT04052555 Phase 1 ATR Kinase Inhibitor M6620
5 Genetic Counseling for Breast Cancer Survivors (GC for BC) Completed NCT02451735
6 Longitudinal Observational Study About the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer Completed NCT03669952
7 Establishment of Normal High Risk Breast Epithelial Cell Cultures, and A High Risk Cell Line and Tissue Repository From Breast Tissue From Women at High Risk of Breast Cancer Completed NCT00032201
8 Genome-Wide Association Study of Radiation Exposure and Bilateral Breast Cancer Active, not recruiting NCT00903591

Search NIH Clinical Center for Bilateral Breast Cancer

Sources

Genetic Tests for Bilateral Breast Cancer

About this section
Sources

Anatomical Context for Bilateral Breast Cancer

About this section

MalaCards organs/tissues related to Bilateral Breast Cancer:

41
Breast, Lymph Node, Testes, Prostate, Skin, Ovary, Lung
Sources

Publications for Bilateral Breast Cancer

About this section

Articles related to Bilateral Breast Cancer:

(show top 50) (show all 814)
# Title Authors PMID Year
1
A novel de novo BRCA2 mutation of paternal origin identified in a Spanish woman with early onset bilateral breast cancer. 9 38
19649703 2010
2
A novel BRCA2 mutation that segregates with breast and prostate cancer in a Spanish family. 9 38
19288190 2010
3
Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. 9 38
20104584 2010
4
Robotic resection of intraductal neoplasm of the pancreas. 9 38
19698031 2009
5
A novel deletion of BRCA1 gene that eliminates the ATG initiation codon without affecting the promoter region. 9 38
19393826 2009
6
Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer. 9 38
19372713 2009
7
Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. 9 38
19153073 2009
8
Accuracy of the BRCAPRO model among women with bilateral breast cancer. 9 38
19127556 2009
9
Identification of a de novo BRCA1 mutation in a woman with early onset bilateral breast cancer. 9 38
19629752 2009
10
Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer. 9 38
18264724 2008
11
Altered DNA binding by the human Rad51-R150Q mutant found in breast cancer patients. 9 38
17666788 2007
12
[Analysis of the mutation of BRCA1 gene in 70 Uigur women breast cancer patients in Xinjiang]. 9 38
17557253 2007
13
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. 9 38
16331614 2006
14
Association of common ATM polymorphism with bilateral breast cancer. 9 38
15756685 2005
15
A comparison of bilateral breast cancers in BRCA carriers. 9 38
15941968 2005
16
BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients. 9 38
15319244 2004
17
ATM variants 7271T>G and IVS10-6T>G among women with unilateral and bilateral breast cancer. 9 38
14562025 2003
18
Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. 9 38
12673797 2003
19
Sex hormone-binding globulin polymorphisms in familial and sporadic breast cancer. 9 38
12151349 2002
20
BRCA1 and BRCA2 mutations in Russian familial breast cancer. 9 38
11793480 2002
21
Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing. 9 38
11802208 2002
22
Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer. 9 38
11556836 2001
23
BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age. 9 38
11389159 2001
24
Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families. 9 38
11149425 2001
25
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. 9 38
11130383 2000
26
Frequency of germ-line BRCA1 mutations among Spanish families from a Mediterranean area. 9 38
10737987 2000
27
Detection of BRCA1 and BRCA2 mutations in breast cancer families by a comprehensive two-stage screening procedure. 9 38
10699917 2000
28
Identification of Rad51 alteration in patients with bilateral breast cancer. 9 38
10807537 2000
29
BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer. 9 38
10573018 1999
30
Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2. 9 38
10188893 1999
31
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. 9 38
9333265 1997
32
Abnormal FHIT transcripts in human breast carcinomas: a clinicopathological and epidemiological analysis of 61 Japanese cases. 9 38
9157994 1997
33
BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. 9 38
9145677 1997
34
Germline mutation of BRCA1 in Japanese breast cancer families. 9 38
7627958 1995
35
Estrogen and progesterone receptor content in bilateral breast cancer. 9 38
7651928 1995
36
Genetic analysis of the BRCA1 region in a large breast/ovarian family: refinement of the minimal region containing BRCA1. 9 38
8281142 1993
37
Bilateral breast cancer: one disease or two? 9 38
1663803 1991
38
Bilateral erector spinae nerve block using one injection for bilateral breast cancer surgery. 38
30776776 2019
39
High relative levels of satellite alpha transcripts predict increased risk of bilateral breast cancer and multiple primary cancer in patients with breast cancer and lacking BRCA‑related clinical features. 38
31173247 2019
40
From uncertainty to pathogenicity: clinical and functional interrogation of a rare TP53 in-frame deletion. 38
30886117 2019
41
The yield of full BRCA1/2 genotyping in Israeli Arab high-risk breast/ovarian cancer patients. 38
31368036 2019
42
Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan. 38
30309218 2019
43
Synchronous and Metachronous bilateral breast Cancer: Clinicopathologic characteristics and prognostic outcomes. 38
31351153 2019
44
National trends of synchronous bilateral breast cancer incidence in the United States. 38
31325072 2019
45
Pseudo skin flash on VMAT in breast radiotherapy: Optimization of virtual bolus thickness and HU values. 38
31221409 2019
46
Local Tumor Staging of Breast Cancer: Digital Mammography versus Digital Mammography Plus Tomosynthesis. 38
30964425 2019
47
Differential Profile of BRCA1 vs. BRCA2 Mutated Families: A Characterization of the Main Differences and Similarities in Patients. 38
31244284 2019
48
The prognostic comparison among unilateral, bilateral, synchronous bilateral, and metachronous bilateral breast cancer: A meta-analysis of studies from recent decade (2008-2018). 38
31038845 2019
49
Does race predict survival for women with invasive breast cancer? 38
31206623 2019
50
Tamoxifen related Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT): A case report and literature review of this possible association. 38
30799070 2019
Sources

Variations for Bilateral Breast Cancer

About this section

ClinVar genetic disease variations for Bilateral Breast Cancer:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 ATM NM_000051.3(ATM): c.2021A> G (p.His674Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs201762714 11:108124663-108124663 11:108253936-108253936
Sources

Expression for Bilateral Breast Cancer

About this section
Search GEO for disease gene expression data for Bilateral Breast Cancer.
Sources

Pathways for Bilateral Breast Cancer

About this section

Pathways related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Gene Expression 66
Show member pathways
 13.56 PGR ESR1 ERBB2 CHEK2 BRCA1 ATM
2
Cell Cycle, Mitotic 66
Show member pathways
 13.2 RAD51 CHEK2 BRCA2 BRCA1 ATM
3
DNA Double-Strand Break Repair 66
Show member pathways
 13 RAD51 CHEK2 BRCA2 BRCA1 ATM
4
TCR Signaling (Qiagen) 64
Show member pathways
 12.74 RAD51 CHEK2 BRCA2 BRCA1 ATM
5
Pathways in cancer 37
12.64 RAD51 ESR1 ERBB2 BRCA2
6
Gastric cancer 37
Show member pathways
 12.54 PGR ESR1 ERBB2 BRCA2 BRCA1
7
Glioma 37
Show member pathways
 12.39 FHIT ESR1 ERBB2 BRCA2 BRCA1 ATM
8
Meiosis 66
Show member pathways
 12.35 RAD51 BRCA2 BRCA1 ATM
9
DNA Damage 4
12.3 RAD51 CHEK2 BRCA2 BRCA1 ATM
10
Apoptosis Pathway 71
Show member pathways
 12.25 ERBB2 CHEK2 ATM
11
Chks in Checkpoint Regulation 64
Show member pathways
 12.24 RAD51 ESR1 CHEK2 BRCA2 BRCA1 ATM
12
DNA Damage Response 1
Show member pathways
 12.23 RAD51 CHEK2 BRCA1 ATM
13
DNA Double Strand Break Response 66
Show member pathways
 12.18 CHEK2 BRCA1 ATM
14
Homologous DNA Pairing and Strand Exchange 66
Show member pathways
 12.13 RAD51 BRCA2 BRCA1 ATM
15
p53 Signaling 64
Show member pathways
 12.07 CHEK2 BRCA1 ATM
16
Cell cycle Role of SCF complex in cell cycle regulation 22
Show member pathways
 12.06 PGR ESR1 CHEK2 BRCA1
17
Signaling by ERBB4 66
Show member pathways
 11.81 PGR ESR1 ERBB2
18
Fanconi anemia pathway 66 37
11.74 RAD51 BRCA2 BRCA1
19
ATM Pathway 64
Show member pathways
 11.64 RAD51 CHEK2 BRCA1 ATM
20
Platinum drug resistance 37
11.62 ERBB2 BRCA1 ATM
21
Pathways Affected in Adenoid Cystic Carcinoma 1
11.49 ERBB2 CHEK2 BRCA1 ATM
22
Integrated Cancer Pathway 1
11.39 CHEK2 BRCA1 ATM
23
DNA damage_ATM/ATR regulation of G1/S checkpoint 22
11.34 CHEK2 BRCA1 ATM
24
FOXA1 transcription factor network 1
Show member pathways
 11.33 ESR1 BRCA1
25
ATM Signaling Network in Development and Disease 1
11.32 CHEK2 ATM
26
Cell cycle Role of 14-3-3 proteins in cell cycle regulation 22
Show member pathways
 11.31 CHEK2 ATM
27
Integrated Breast Cancer Pathway 1
11.29 RAD51 ESR1 CHEK2 BRCA2 BRCA1 ATM
28
BRCA1 Pathway 64
Show member pathways
 11.27 RAD51 CHEK2 BRCA2 BRCA1 ATM
29
DNA damage_Role of Brca1 and Brca2 in DNA repair 22
11.26 RAD51 CHEK2 BRCA2 BRCA1 ATM
30
FOXM1 transcription factor network 1
11.24 ESR1 CHEK2 BRCA2
31
Ovarian Infertility Genes 1
11.14 PGR ATM
32
GADD45 Pathway 64
11.14 BRCA1 ATM
33
BARD1 signaling events 1
11.1 RAD51 BRCA1 ATM
34
Gemtuzumab ozogamicin Pathway, Pharmacokinetics/Pharmacodynamics 61
10.99 CHEK2 ATM
35
DNA Damage Induced 14-3-3Sigma Signaling 64
10.89 BRCA1 ATM
Sources

GO Terms for Bilateral Breast Cancer

About this section

Cellular components related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.87 RAD51 PGR ESR1 CHEK2 BRCA2 BRCA1
2 cytoplasm GO:0005737 9.81 RAD51 PGR FHIT ESR1 ERBB2 CHEK2
3 protein-containing complex GO:0032991 9.67 RAD51 ESR1 BRCA2 BRCA1
4 nucleus GO:0005634 9.61 RAD51 PGR FHIT ESR1 ERBB2 CHEK2
5 condensed nuclear chromosome GO:0000794 9.43 RAD51 BRCA1
6 nuclear chromosome, telomeric region GO:0000784 9.43 RAD51 BRCA2 ATM
7 condensed chromosome GO:0000793 9.4 RAD51 BRCA1
8 lateral element GO:0000800 8.8 RAD51 BRCA2 BRCA1

Biological processes related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.91 FHIT CHEK2 BRCA1 ATM
2 cell cycle GO:0007049 9.87 CHEK2 BRCA2 BRCA1 ATM
3 positive regulation of transcription, DNA-templated GO:0045893 9.85 ESR1 CHEK2 BRCA2 BRCA1
4 regulation of apoptotic process GO:0042981 9.8 ESR1 BRCA1 ATM
5 cellular response to DNA damage stimulus GO:0006974 9.72 RAD51 CHEK2 BRCA2 BRCA1 ATM
6 protein autophosphorylation GO:0046777 9.71 ERBB2 CHEK2 ATM
7 DNA recombination GO:0006310 9.65 RAD51 BRCA2 BRCA1
8 response to ionizing radiation GO:0010212 9.63 BRCA1 ATM
9 negative regulation of G0 to G1 transition GO:0070317 9.62 RAD51 BRCA1
10 double-strand break repair via homologous recombination GO:0000724 9.61 RAD51 BRCA2 BRCA1
11 reciprocal meiotic recombination GO:0007131 9.6 RAD51 ATM
12 DNA damage checkpoint GO:0000077 9.59 CHEK2 ATM
13 response to gamma radiation GO:0010332 9.58 CHEK2 BRCA2
14 cellular response to gamma radiation GO:0071480 9.58 CHEK2 ATM
15 double-strand break repair GO:0006302 9.58 CHEK2 BRCA2 BRCA1
16 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.56 CHEK2 BRCA2
17 DNA repair GO:0006281 9.55 RAD51 CHEK2 BRCA2 BRCA1 ATM
18 DNA double-strand break processing GO:0000729 9.52 BRCA1 ATM
19 replicative senescence GO:0090399 9.51 CHEK2 ATM
20 telomere maintenance via recombination GO:0000722 9.49 RAD51 BRCA2
21 DNA damage induced protein phosphorylation GO:0006975 9.46 CHEK2 ATM
22 chordate embryonic development GO:0043009 9.37 BRCA2 BRCA1
23 mammary gland development GO:0030879 9.31 PGR
24 mitotic recombination-dependent replication fork processing GO:1990426 9.26 RAD51 BRCA2
25 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.13 CHEK2 BRCA2 BRCA1
26 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 8.92 CHEK2 BRCA2 BRCA1 ATM

Molecular functions related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.73 RAD51 PGR ESR1 BRCA2 BRCA1 ATM
2 ubiquitin protein ligase binding GO:0031625 9.58 FHIT CHEK2 BRCA1
3 protein C-terminus binding GO:0008022 9.5 RAD51 ERBB2 BRCA2
4 enzyme binding GO:0019899 9.46 RAD51 PGR ESR1 BRCA1
5 nuclear receptor activity GO:0004879 9.43 PGR ESR1
6 steroid binding GO:0005496 9.37 PGR ESR1
7 nucleotide binding GO:0000166 9.35 RAD51 FHIT ERBB2 CHEK2 ATM
8 identical protein binding GO:0042802 9.23 RAD51 PGR FHIT ESR1 ERBB2 CHEK2
Sources

Sources for Bilateral Breast Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....